Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce it has completed a pre-Investigational New Drug ("IND") interaction with the U.S. Food and Drug Administration (FDA) and received positive feedback on its development program for KTX-1161 for corneal endothelial disease. KTX-1161 is a topical ophthalmic solution formulation of SCO-116, a novel Nrf2 activator being developed under a license